Tumour necrosis factor blockade did not prevent the increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritis rats

Journal of Endocrinology

Volumn 191, Issue 1, 2006, Pages 319-326

  Granado, M ^a   Martin A I ^a   Priego, T ^a   Lopez Calderon A ^a   Villanua M A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; MUSCLE ACTROPHY F BOX PROTEIN; MUSCLE RING FINGER 1; PEGYLATED TUMOR NECROSIS FACTOR RECEPTOR 1; SODIUM CHLORIDE; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; MALE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; RHEUMATOID ARTHRITIS; SKELETAL MUSCLE; TISSUE DISTRIBUTION; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR I; MALE; MUSCLE PROTEINS; MUSCLE, SKELETAL; RATS; RATS, WISTAR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKP CULLIN F-BOX PROTEIN LIGASES; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES;

EID: 33751038124     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06931     Document Type: Article

References (48)

1. Awede B, Thissen J, Gailly P & Lebacq J 1999 Regulation of IGF-I, IGFBP-4 and IGFBP-5 gene expression by loading in mouse skeletal muscle. FEBS Letters 461 263-267.
2. Bar T, Stahlberg A, Muszta A & Kubista M 2003 Kinetic outlier detection (KOD) in real-time PCR. Nucleic Acids Research 31 e105.
3. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K et al. 2001 Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294 1704-1708.
4. Broussard SR, McCusker RH, Novakofski JE, Strle K, Shen WH, Johnson RW, Freund GG, Dantzer R & Kelley KW 2003 Cytokine-hormone interactions: tumor necrosis factor α impairs biologic activity and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. Endocrinology 144 2988-2996.
5. Bush KA, Walker JS, Frazier J & Kirkham BW 2002 Effects of a PEGylated soluble TNF receptor type 1 (PEG sTNF-RI) on cytokine expression in adjuvant arthritis. Scandinavian Journal of Rheumatology 31 198-204.
6. Chrysis D & Underwood LE 1999 Regulation of components of the ubiquitin system by insulin-like growth factor I and growth hormone in skeletal muscle of rats made catabolic with dexamethasone. Endocrinology 140 5635-5641.
7. Combaret L, Tilignac T, Claustre A, Voisin L, Taillandier D, Obled C, Tanaka K & Attaix D 2002 Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin-proteasome-dependent proteolysis in cancer and septic rats. Biochemical Journal 361 185-192.
8. Cooney R, Kimball SR, Eckman R, Maish G, III, Shumate M & Vary TC 1999 TNF-binding protein ameliorates inhibition of skeletal muscle protein synthesis during sepsis. American Journal of Physiology 276 E611-E619.
9. Costelli P, Carbo N, Tessitore L, Bagby GJ, López-Soriano FJ, Argiles JM & Baccino FM 1993 Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. Journal of Clinical Investigation 92 2783-2789.
10. Dehoux MJM, van Beneden RP, Fernández-Celemín L, Lause PL & Thissen JPM 2003 Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. FEBS Letters 544 214-217.
11. Dehoux M, Van Beneden R, Pasko N, Lause P, Verniers J, Underwood L, Ketelslegers JM & Thissen JP 2004 Role of the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx: during fasting and diabetes. Endocrinology 145 4806-4812.
12. Ding H, Gan XL, Hirschberg R, Vadgana. JV & Kopple JD 1996 Impaired actions of insulin-like growth factor I on protein synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. Journal of Clinical Investigation 97 1064-1075.
13. Fang CH, Li BG, Sun X & Hasselgren PO 2000 Insuhn-like growth factor I reduces ubiquitin and ubiquitin-conjugating enzyme gene expression but does not inhibit muscle proteolysis in septic rats. Endocrinology 141 2743-2751.
14. Fernández-Celemín L, Pasko N, Blomart V & Thissen JP 2002 Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-α. American Journal of Physiology 283 E1279-E1290.
15. Figueras M, Busquets S, Carbo N, Almendro V, Argiles JM & Lopez-Soriano FJ 2005 Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue. International Journal of Oncology 27 855-860.
16. Foulstone EJ, Meadows KA, Holly JM & Stewart CE 2001 Insulin-like growth factors (IGF-I and IGF-II) inhibit C2 skeletal myoblast differentiation and enhance TNF alpha-induced apoptosis. Journal of Cellular Physiology 189 207-215.
17. Gomes MD, Lecker SH,Jagoe RT, Navon A & Goldberg AL 2001 Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. PNAS 98 14440-14445.
18. Granado M, Priego T, Martín AI, Villanúa MA & López-Calderón A 2005 The ghrelin receptor agonist GHRP-2, prevents artritis-induced increase in E3 ubiquitin-ligating encimes MuRF1 and MAFbx gene expression in skeletal muscle. American Journal of Physiology 289 E1007-E1014.
19. Granado M, Priego T, Martín AI, Vara E, López-Calderón A & Villanúa MA 2006 Anti-tumor necrosis factor agent PEG-sTNFRI improves the growth hormone/ insulin-like growth factor-I system in adjuvant-induced arthritic rats. European Journal of Pharmacology 536 204-210.
20. Hamada K, Vannier E, Smith DE, Abad LW & Roubenoff R 2000 Inflammatory cachexia induces sarcoactive cytokine gene expression in a rat model of adjuvant arthritis. Journal of the Federation for the American Society for Experimental Biology 14 A572 (Abstract).
21. Hasselgren PO, James JH, Benson DW, Hall-Angeras M, Angeras U, Hiyama DT, Lis S & Fischer JE 1989 Total and myofibrillar protein breakdown in different types of rat skeletal muscle: effects of sepsis and regulation by insulin. Metabolism 38 634-640.
22. Hershko A, Ciechanover A & Varshavsky A 2000 The ubiquitin system. Nature Medicine 6 1073-1081.
23. Hitt A, Graves E & McCarthy DO 2005 Indomethacin preserves muscle mass and reduces levels of E3 ligases and TNF receptor type 1 in the gastrocnemius muscle of tumor-bearing mice. Research in Nursing & Health 28 56-66.
24. Hoshino E, Pichard C, Greenwood CE, Kuo GC, Cameron RG, Kurian R, Kearns JP, Allard JP & Jeejeebhoy KN 1991 Body composition and metabolic rate in rat during a continuous infusion of cachectin. American Journal of Physiology 260 E27-E36.
25. Ibáñez de Cáceres I, Villanúa M, Soto L, Martín AI & López-Calderón A 2000 Insulin-like growth factor (IGF-I) and IGF-binding proteins in rats with adjuvant-induced arthritis given recombinant human growth hormone. Journal of Endocrinology 165 537-544.
26. Lang CH, Frost RA, Jefferson LS, Kimball SR & Vary TC 2000 Endotoxin-induced decrease in muscle protein synthesis is associated with changes in dIF2B, eIF4E, and IGF-I. American Journal of Physiology 278 E1133-E1144.
27. Lang CH, Nystrom GJ & Frost RA 2002 Burn-induced changes in IGF-I and IGF-binding proteins are partially glucocorticoid dependent. American Journal of Physiology 282 R207-R215.
28. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE & Goldberg AL 2004 Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB Journal 18 39-51.
29. Livak KJ & Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] method. Methods 25 402-408.
30. Llovera M, Carbo N, García-Martínez C, Costelli P, Tessitore L, Baccino FM, Agell N, Bagby GJ, Lopez-Soriano F & Argiles JM 1996 Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. Biochemical and Biophysical Research Communications 221 653-655.
31. Llovera M, García-Martinez C, Agell N, Lopez-Soriano FJ & Argiles JM 1997 TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochemical and Biophysical Research Communications 230 238-241.
32. Llovera M, García-Martinez C, López-Soriano J, Carbó N, Agell N, Lopez-Soriano FJ & Argiles JM 1998 Role of TNF receptor-1 in protein turnover during cancer cachexia using gene knockout mice. Molecular and Cellular Endocrinology 142 183-189.
33. Mitch WE & Goldberg AL 1996 Mechanisms of muscle wasting: the role of the ubiquitin-proteasome pathway. New England Journal of Medicine 335 1897-1905.
34. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL & Rosenthal N 2001 Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genetics 27 195-200.
35. Oliver WT, Rosenberger J, Lopez R, Gomez A, Cummings KK & Fiorotto ML 2005 The local expression and abundance of insulin-like growth factor (IGF) binding proteins in skeletal muscle are regulated by age and gender but not local IGF-I in vivo. Endocrinology 146 5455-5462.
36. Olney RC, Tsuchiya K, Wilson DM, Mohtai M, Maloney WJ, Schurman DJ & Smith RL 1996 Chondrocytes from osteoarthritic cartilage have increased expression of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) and -5, but not IGF-II or IGFBP-4. Clinical Endocrinology and Metabolism 81 1096-1113.
37. Roubenoff R, Freeman LM, Smith DE, Abad LW, Dinarello CA & Kehayias JJ 1997 Adjuvant arthritis as a model of inflammatory cachexia. Arthritis and Rheumatism 40 534-539.
38. Salih DA, Tripathi G, Holding C, Szestak TA, Gonzalez MI, Carter EJ, Cobb LJ, Eisemann JE & Pell JM 2004 Insulin-like growth factor-binding protein 5 (Igfbp5) comprises survival, growth, muscle development, and fertility in mice. PNAS 101 4314-4319.
39. Sarzi-Puttini P, Atzeni F, Scholmerich J, Cutolo M & Straub RH 2006 Anti-TNF antibody therapy improves glucocorticoid-induced insulin-like growth factor-1 (IGF-1) resistance without influencing myoglobin and IGF-1 binding proteins 1 and 3. Annals of the Rheumatic Diseases 65 301-305.
40. Schneider MR, Wolf E, Hoeflich A & Lahm H 2002 IGF-binding protein-5: flexible player in the IGF system and effector on its own. Journal of Endocrinology 172 423-440.
41. Solorzano CC, Kaibara A, Hess PJ, Edwards PD, Ksontini R, Abouhamze A, McDaniel S, Frazier J, Trujillo D, Kieft G et al. 1998 Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. Journal of Applied Physiology 84 1119-1130.
42. Sunic D, McNeil JD, Rayner TE, Andress DL & Belford DA 1998 Regulation of insulin-like growth factor-binding protein-5 by insulin-like growth factor I and interleukin-1α in ovine articular chondrocytes. Endocrinology 139 2356-2362.
43. Tanaka H, Ueta Y, Yamashita U, Kannan M & Yamashita H 1996 Biphasic changes in behavioural, endocrine and sympathetic systems in adjuvant artritis in Lewis rats. Brain Research Bulletin 39 33-37.
44. Tisdale MJ 2000 Protein loss in cancer cachexia. Science 289 2293-2294.
45. Tracey KJ, Morgello S, Koplin B, Fahey TJ, Fox J, Aledo A, Manogue KR & Cerami A 1990 Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. Journal of Clinical Investigation 86 2014-2024.
46. Vary T, Dardevet D, Grizard J, Voisin L, Buffiere C, Denis P, Breuille D & Obled C 1999 Pentoxifylline improves insulin action limiting skeletal muscle catabolism after infection. Journal of Endocrinology 163 15-24.
47. Warne JP 2003 Tumor necrosis factor α: a key regulator of adipose tissue mass. Journal of Endocrinology 177 351-355.
48. Yumet G, Shumate ML, Bryant P, Lin CM, Lang CH & Cooney RN 2002 Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis. American Journal of Physiology 283 E472-E481.